Acknowledgements
The authors would like to thank all the ALS Measure Development Work Group Members for their contributions and work that supported the development of this manuscript: Robert G. Miller, MD (neurology); Benjamin Rix Brooks, MD (neurology); Steven Ringel, MD (neurology); Hiroshi Mitsumoto, MD (neurology); Carlayne Jackson, MD (neurology); Christen Shoesmith, MD, BSc (neurology); Edward Kasarskis, MD, PhD (neurology); Robert C. Basner, MD (pulmonology); Nicholas Procaccini, MD (gastroenterology); Gregory Carter, MD (physical medicine and rehabilitation); Dallas Forshew, RN, BSN (nursing); Mohammed Sanjak, PhD, PT, MBA (physical therapy/occupational therapy); Pat Casey, MS, CRCC (physical therapy/occupational therapy); Bob Osborne RN (hospice/palliative care); Valerie Cwik, MD (Muscular Dystrophy Association); Christine Jasch OTR/L)(patient representative); Fredrik Tolin, MD, MBA (Humana); Rebecca J. Swain-Eng, MS, CAE (AAN staff); Gina Gjorvad (AAN staff); Rebecca Kresowik (methodologist); Richard Dubinsky, MD (facilitator); Joel Kaufman, MD (facilitator); Adam Cohen, MD (facilitator); Christopher Bever, MD (AAN QMR); Eric Cheng, MD, MS (AAN QMR). The authors would also like to thank the Muscular Dystrophy Association for their support in the development of the measures.
Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.